• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与某些苯二氮䓬类药物不同,环吡咯酮类药物不会使小鼠产生身体依赖性。

Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice.

作者信息

Piot O, Betschart J, Stutzmann J M, Blanchard J C

机构信息

Rhône-Poulenc Santé, Centre de Recherches de Vitry-Alfortville, Vitry sur Seine, France.

出版信息

Neurosci Lett. 1990 Sep 4;117(1-2):140-3. doi: 10.1016/0304-3940(90)90133-t.

DOI:10.1016/0304-3940(90)90133-t
PMID:2290609
Abstract

In a model of physical dependence in mice, treatment with cyclopyrrolones such as zopiclone and suriclone (from 4 to 400 mg/kg/day), did not modify the sensitivity of the gamma-aminobutyric acid (GABA) receptor complex to the partial inverse agonist FG 7142 following their withdrawal, whereas sensitivity changes were observed after treatment and withdrawal from some benzodiazepines (e.g. lorazepam, diazepam, flunitrazepam and triazolam). These data suggest that, in contrast to some benzodiazepines, zopiclone and suriclone may not produce physical dependence.

摘要

在小鼠身体依赖性模型中,使用诸如佐匹克隆和舒立克隆等环吡咯酮(剂量为4至400毫克/千克/天)进行治疗,在撤药后并未改变γ-氨基丁酸(GABA)受体复合物对部分反向激动剂FG 7142的敏感性,而在使用某些苯二氮䓬类药物(如劳拉西泮、地西泮、氟硝西泮和三唑仑)治疗并撤药后则观察到了敏感性变化。这些数据表明,与某些苯二氮䓬类药物不同,佐匹克隆和舒立克隆可能不会产生身体依赖性。

相似文献

1
Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice.与某些苯二氮䓬类药物不同,环吡咯酮类药物不会使小鼠产生身体依赖性。
Neurosci Lett. 1990 Sep 4;117(1-2):140-3. doi: 10.1016/0304-3940(90)90133-t.
2
The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines.环吡咯酮类药物对γ-氨基丁酸A型(GABAA)受体功能的影响与苯二氮䓬类药物不同。
Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):294-300. doi: 10.1007/BF00175035.
3
Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors.抗焦虑环吡咯酮类药物佐匹克隆和舒里克隆与一个与苯二氮䓬受体变构连接的新位点结合。
Mol Pharmacol. 1984 Nov;26(3):458-69.
4
Pharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone.环吡咯酮类药物的药理及临床研究:佐匹克隆与舒里克隆
Pharmacol Biochem Behav. 1985 Oct;23(4):653-9. doi: 10.1016/0091-3057(85)90433-2.
5
Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?亚型选择性γ-氨基丁酸A受体调节剂诱导小鼠身体依赖性的倾向是否降低?
J Pharmacol Exp Ther. 2006 Mar;316(3):1378-85. doi: 10.1124/jpet.105.094474. Epub 2005 Dec 13.
6
Effects of zopiclone and benzodiazepine hypnotics on search in short-term memory.佐匹克隆和苯二氮䓬类催眠药对短期记忆搜索的影响。
Neuropsychobiology. 1984;12(4):244-8. doi: 10.1159/000118146.
7
Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum.舒立克隆:一种新型环吡咯酮衍生物,可识别大鼠海马体和小脑中由苯二氮䓬标记的受体。
J Neurochem. 1983 Mar;40(3):601-7. doi: 10.1111/j.1471-4159.1983.tb08023.x.
8
Differences between cyclopyrrolones (suriclone and zopiclone) and benzodiazepine binding to rat hippocampus photolabelled membranes.
Biochem Pharmacol. 1983 Dec 1;32(23):3651-3. doi: 10.1016/0006-2952(83)90318-0.
9
Benzodiazepine withdrawal syndrome seizures.苯二氮䓬类药物戒断综合征性癫痫发作
Pharmacopsychiatry. 1995 Nov;28(6):257-62. doi: 10.1055/s-2007-979613.
10
Partial chemical characterization of cyclopyrrolones ([3H] suriclone) and benzodiazepines ([3H]flunitrazepam) binding site: differences.
Life Sci. 1985 Jun 10;36(23):2247-55. doi: 10.1016/0024-3205(85)90336-4.

引用本文的文献

1
Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.佐匹克隆。对其作为催眠药的药理特性和治疗效果的综述。
Drugs Aging. 1993 Sep-Oct;3(5):441-59. doi: 10.2165/00002512-199303050-00006.
2
The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines.环吡咯酮类药物对γ-氨基丁酸A型(GABAA)受体功能的影响与苯二氮䓬类药物不同。
Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):294-300. doi: 10.1007/BF00175035.